a developer of novel gene therapies to treat patients with sight-threatening ophthalmic diseases
Industry Biotechnology
A.I.dvisor tells us that ADVM and IMNM have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ADVM and IMNM's prices will move in lockstep.
Ticker / NAME | Correlation To ADVM | 1D Price Change % | ||
---|---|---|---|---|
ADVM | 100% | -2.59% | ||
IMNM - ADVM | 33% Poorly correlated | -7.51% | ||
KPTI - ADVM | 29% Poorly correlated | -5.29% | ||
FDMT - ADVM | 26% Poorly correlated | -1.80% | ||
ORIC - ADVM | 22% Poorly correlated | -2.89% | ||
TENX - ADVM | 22% Poorly correlated | -3.26% | ||
More |
Ticker / NAME | Correlation To ADVM | 1D Price Change % |
---|---|---|
ADVM | 100% | -2.59% |
gene therapy theme (13 stocks) | 26% Poorly correlated | +1.26% |
ophthalmology theme (8 stocks) | 16% Poorly correlated | +1.16% |
biotechnology theme (248 stocks) | 12% Poorly correlated | +5.56% |
surgery theme (21 stocks) | 6% Poorly correlated | -0.29% |